Company intelligence / Profile preview

Cali Pharmaceuticals

San Diego, California, USAcalibiosciences.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Cali Pharmaceuticals is advancing CPL‑01, an extended-release formulation of ropivacaine for perioperative pain. The company has completed a Phase 2b trial showing promising efficacy and safety results in postoperative pain after bunionectomy. Two pivotal Phase 3 studies are ongoing to further evaluate efficacy and opioid-sparing effects in surgical patients.[3][5]

Therapeutic areas: Other
Modalities: Small molecules (noted for 505(b)(2) product development and injectable formulations)[2]Extended-release injectables[5]
Industry: Biotech

Drug pipeline

1 asset

ropivacaine

Phase 2

Indications: Postoperative acute pain

Partnerships

Grand Life Sciences announced strategic collaboration with parent company for commercialization of CPL‑01.[1]

Beyond the preview

Go deeper on Cali Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cali Pharmaceuticals.

Explore the full profile